118 related articles for article (PubMed ID: 16466700)
1. c-Myc over-expression in Ramos Burkitt's lymphoma cell line predisposes to iron homeostasis disruption in vitro.
Habel ME; Jung D
Biochem Biophys Res Commun; 2006 Mar; 341(4):1309-16. PubMed ID: 16466700
[TBL] [Abstract][Full Text] [Related]
2. Iron specific growth inhibition of Burkitt's lymphoma cells in vitro, associated with a decrease in translocated c-myc expression.
Habel ME; Lemieux R; Jung D
J Cell Physiol; 2005 Apr; 203(1):277-85. PubMed ID: 15468060
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the E mu enhancer.
Cutrona G; Carpaneto EM; Ponzanelli A; Ulivi M; Millo E; Scarfì S; Roncella S; Benatti U; Boffa LC; Ferrarini M
Cancer Res; 2003 Oct; 63(19):6144-8. PubMed ID: 14559793
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells.
Sampson VB; Rong NH; Han J; Yang Q; Aris V; Soteropoulos P; Petrelli NJ; Dunn SP; Krueger LJ
Cancer Res; 2007 Oct; 67(20):9762-70. PubMed ID: 17942906
[TBL] [Abstract][Full Text] [Related]
5. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT
Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737
[TBL] [Abstract][Full Text] [Related]
6. c-MYC impairs immunogenicity of human B cells.
Schlee M; Schuhmacher M; Hölzel M; Laux G; Bornkamm GW
Adv Cancer Res; 2007; 97():167-88. PubMed ID: 17419945
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.
Marampon F; Ciccarelli C; Zani BM
Mol Cancer; 2006 Aug; 5():31. PubMed ID: 16899113
[TBL] [Abstract][Full Text] [Related]
8. Regulation of transferrin receptor 2 in human cancer cell lines.
Calzolari A; Finisguerra V; Oliviero I; Deaglio S; Mariani G; Malavasi F; Testa U
Blood Cells Mol Dis; 2009; 42(1):5-13. PubMed ID: 19019709
[TBL] [Abstract][Full Text] [Related]
9. The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line.
Bemark M; Neuberger MS
Oncogene; 2000 Jul; 19(30):3404-10. PubMed ID: 10918597
[TBL] [Abstract][Full Text] [Related]
10. Involvement of Myc targets in c-myc and N-myc induced human tumors.
Ben-Yosef T; Yanuka O; Halle D; Benvenisty N
Oncogene; 1998 Jul; 17(2):165-71. PubMed ID: 9674700
[TBL] [Abstract][Full Text] [Related]
11. The block of elongation in c-myc exon 1 is abolished in Burkitt's lymphoma cell lines with variant translocation.
Eick D; Polack A; Kofler E; Bornkamm GW
Oncogene; 1988 Oct; 3(4):397-403. PubMed ID: 3078949
[TBL] [Abstract][Full Text] [Related]
12. Free radicals act as effectors in the growth inhibition and apoptosis of iron-treated Burkitt's lymphoma cells.
Habel ME; Jung D
Free Radic Res; 2006 Aug; 40(8):789-97. PubMed ID: 17015257
[TBL] [Abstract][Full Text] [Related]
13. Expression of the subgenomic hepatitis C virus replicon alters iron homeostasis in Huh7 cells.
Fillebeen C; Muckenthaler M; Andriopoulos B; Bisaillon M; Mounir Z; Hentze MW; Koromilas AE; Pantopoulos K
J Hepatol; 2007 Jul; 47(1):12-22. PubMed ID: 17399844
[TBL] [Abstract][Full Text] [Related]
14. Transferrin receptor 2 is frequently expressed in human cancer cell lines.
Calzolari A; Oliviero I; Deaglio S; Mariani G; Biffoni M; Sposi NM; Malavasi F; Peschle C; Testa U
Blood Cells Mol Dis; 2007; 39(1):82-91. PubMed ID: 17428703
[TBL] [Abstract][Full Text] [Related]
15. c-myc Suppression in Burkitt's lymphoma cells.
Simonsson T; Henriksson M
Biochem Biophys Res Commun; 2002 Jan; 290(1):11-5. PubMed ID: 11779125
[TBL] [Abstract][Full Text] [Related]
16. c-Myc and eIF4F are components of a feedforward loop that links transcription and translation.
Lin CJ; Cencic R; Mills JR; Robert F; Pelletier J
Cancer Res; 2008 Jul; 68(13):5326-34. PubMed ID: 18593934
[TBL] [Abstract][Full Text] [Related]
17. Decreased accessibility of globotriaosylceramide associated with decreased tumorigenicity in Burkitt's lymphoma variants induced by immunoselection.
Junqua S; Larsen AK; Wils P; Mishal Z; Wiels J; Le Pecq JB
Cancer Res; 1989 Dec; 49(23):6480-6. PubMed ID: 2684394
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib inhibits Burkitt's lymphoma cell proliferation by downregulating sumoylated hnRNP K and c-Myc expression.
Suk FM; Lin SY; Lin RJ; Hsine YH; Liao YJ; Fang SU; Liang YC
Oncotarget; 2015 Sep; 6(28):25988-6001. PubMed ID: 26317903
[TBL] [Abstract][Full Text] [Related]
19. Coordinated regulation of iron-controlling genes, H-ferritin and IRP2, by c-MYC.
Wu KJ; Polack A; Dalla-Favera R
Science; 1999 Jan; 283(5402):676-9. PubMed ID: 9924025
[TBL] [Abstract][Full Text] [Related]
20. Dissociation of thymidine incorporation and transferrin receptor expression from cell growth and c-myc accumulation in alpha-interferon-treated cells.
Meadows LM; George DJ; Kaufman RE
J Biol Response Mod; 1990 Apr; 9(2):212-20. PubMed ID: 2187953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
